Video

#SaxoStrats
Today's edition of the Saxo Morning Call features the SaxoStrats team discussing the continuing weakness of the US dollar as commodity prices recover ground and in the wake of key US equity indices hitting all-time highs Thursday.
Article / 19 January 2017 at 15:15 GMT

Healthcare equities aren't as healthy as many think – #SaxoStrats

Head of Equity Strategy / Saxo Bank
Denmark
  • Value and contrarian investors begin to return to US healthcare sector
  • Comparing energy and healthcare is a flawed proposition
  • In terms of valuation, healthcare could easily go lower
healthcare flatlining
 Healthcare stocks need some stronger medicine before they're worth it. Photo: iStock

By Peter Garnry

Value and contrarian (mean reversion) investors are beginning to flock back to the US healthcare sector following a dismal 2016. The argument goes something like: “energy was the worst performer in 2015 and see what happened in 2016 – it will happen to health care as well”. 

My main point is that these are not comparable because energy is driven by oil which is a global market controlled by a few players whereas the healthcare sector in the US is a heavy regulated market. Here, direct policy changes have implications and income growth does long-term dictate growth in healthcare.

Our view is that in terms of valuation (see chart below) we could easily go lower as (a) policy uncertainty is becoming fully priced in, (b) margins are lower (and as a result ROIC) due to pricing pressure and (c) lower revenue growth as US households cannot absorb the last 10 years of insane price gains on drugs and health insurance. 

Finally, momentum remains very weak, indicating a higher likelihood of more underperformance during the next three months. President-elect Trump’s remarks on healthcare suggest reforms are coming and they are likely not going to be an advantage to the companies.

US healthcare industry group valuation. 12-month forward EV/EBIDTA ratio (z-score)
healthcare valuation
 Source: Saxo Bank

 – Edited by Clare MacCarthy

 

Peter Garnry is head of equity strategy at Saxo Bank

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Tradingfloor.com permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Tradingfloor.com and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Tradingfloor.com is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Tradingfloor.com or as a result of the use of the Tradingfloor.com. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through Tradingfloor.com your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. Tradingfloor.com does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail